Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 1/2010

01-01-2010 | Clinical Research

Overexpression of 11β-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients

Authors: René Baudrand, Cristian A. Carvajal, Arnoldo Riquelme, Mauricio Morales, Nancy Solis, Margarita Pizarro, Alex Escalona, Camilo Boza, Gustavo Pérez, Angélica Domínguez, Marco Arrese, Carlos E. Fardella

Published in: Obesity Surgery | Issue 1/2010

Login to get access

Abstract

Background

The enzyme 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes intracellular glucocorticoid reactivation by conversion of cortisone to cortisol in different tissues and have been implicated in several metabolic disorders associated with obesity. The aim of this study was to evaluate the 11β-HSD1 expression in liver, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) in morbidly obese patients undergoing bariatric surgery and its correlations with clinical, anthropometric, and biochemical variables.

Methods

A prospective study was conducted over a 27-month period. Hepatic, VAT, and SAT samples were obtained at the time of surgery. 11β-HSD1 and 18S gene expression was measured using real-time quantitative reverse transcriptase-polymerase chain reaction.

Results

Forty nine patients met the inclusion criteria [mean age: 42.2 ± 10 years, body mass index (BMI): 42 ± 6 kg/m2, 71% women and 63% with metabolic syndrome (MS)]. 11β-HSD1 mRNA levels were higher in liver than fat tissue (p < 0.001), being higher in SAT than in VAT (p < 0.001) without gender-specific differences. Hepatic expression of 11β-HSD1 correlated positively with SAT and VAT, alanine aminotransferase (ALT), and serum glucose and was inversely associated with BMI. 11β-HSD1 mRNA in VAT correlated positively with insulinemia, ALT, and LDL cholesterol. There were no associations between 11β-HSD1 mRNA in SAT and the variables analyzed.

Conclusions

11β-HSD1 expression is higher in liver in comparison to adipose tissue in obese patients. The observed correlations between hepatic and VAT 11β-HSD1 expression with dyslipidemia and insulin resistance suggest that this enzyme might have a pathogenic role in obesity and related metabolic disorders.
Literature
1.
Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.CrossRefPubMed
2.
Dandona P, Aljada A, Chaudhuri A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448–54.CrossRefPubMed
3.
Tataranni PA. Metabolic syndrome: is there a pathophysiological common denominator? World Rev Nutr Diet. 2005;94:75–83.CrossRefPubMed
4.
National Cholesterol Education Program. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRef
5.
Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.CrossRefPubMed
6.
Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399–408.CrossRefPubMed
7.
Salgado Junior W, Santos JS, Sankarankutty AK, et al. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras. 2006;21(Suppl 1):72–8.PubMed
8.
Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing's disease of the omentum”? Lancet. 1997;349:1210–3.CrossRefPubMed
9.
Siminialayi IM, Emem-Chioma PC. Glucocorticoids and the insulin resistance syndrome. Niger J Med. 2004;13:330–5.PubMed
10.
Krozowski Z, Li KX, Koyama K, et al. The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol. 1999;69:391–401.CrossRefPubMed
11.
Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab. 1998;83:1325–35.CrossRefPubMed
12.
Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004;25:831–66.CrossRefPubMed
13.
Bujalska IJ, Walker EA, Tomlinson JW, et al. 11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr Res. 2002;28:449–61.CrossRefPubMed
14.
Atanasov AG, Nashev LG, Schweizer RA. et al Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett. 2004;571:129–33.CrossRefPubMed
15.
Freeman L, Hewison M, Hughes SV, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood. 2005;106:2042–9.CrossRefPubMed
16.
Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166–70.CrossRefPubMed
17.
Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A. 2004;101:7088–93.CrossRefPubMed
18.
Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2004;53:931–8.CrossRefPubMed
19.
Alberti L, Girola A, Gilardini L, et al. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects. Int J Obes (Lond). 2007;31:1826–31.CrossRef
20.
Paulsen SK, Pedersen SB, Fisker S, et al. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring). 2007;15:1954–60.CrossRef
21.
Walker BR, Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci. 2006;1083:165–84.CrossRefPubMed
22.
Valsamakis G, Anwar A, Tomlinson JW, et al. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:4755–61.CrossRefPubMed
23.
Berthiaume M, Laplante M, Festuccia WT, et al. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab. 2007;293:E1045–52.CrossRefPubMed
24.
Atanasov AG, Odermatt A. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity? Endocr Metab Immune Disord Drug Targets. 2007;7:125–40.CrossRefPubMed
25.
Tomlinson JW, Bujalska I, Stewart PM, et al. The role of 11 beta-hydroxysteroid dehydrogenase in central obesity and osteoporosis. Endocr Res. 2000;26:711–22.CrossRefPubMed
26.
Mariniello B, Ronconi V, Rilli S, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol. 2006;155:435–41.CrossRefPubMed
27.
Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14:794–8.CrossRef
28.
Basu R, Singh RJ, Basu A, et al. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydroxysteroid dehydrogenase (11beta-hsd) type 1 pathway. Diabetes. 2004;53:2051–9.CrossRefPubMed
29.
Munoz R, Carvajal C, Escalona A, et al. 11beta-Hydroxysteroid Dehydrogenase Type 1 is Overexpressed in Subcutaneous Adipose Tissue of Morbidly Obese Patients. Obes Surg. 2009;19:764–70.CrossRefPubMed
30.
Carrasco F, Klaassen J, Papapietro K, et al. A proposal of guidelines for surgical management of obesity. Rev Med Chil. 2005;133:699–706.PubMed
31.
Acosta AM, Escalona M, Miz A, et al. Determination of the insulin resistance index by the Homeostasis Model Assessment in a population of Metropolitan Region in Chile. Rev Med Chil. 2002;130(11):1227–31.PubMed
32.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.CrossRefPubMed
33.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.CrossRefPubMed
34.
Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.CrossRefPubMed
35.
Altuna ME, Lelli SM, de Viale San Martin LC, et al. Effect of stress on hepatic 11beta-hydroxysteroid dehydrogenase activity and its influence on carbohydrate metabolism. Can J Physiol Pharmacol. 2006;84:977–84.CrossRefPubMed
36.
Holmes MC, Kotelevtsev Y, Mullins JJ, et al. Phenotypic analysis of mice bearing targeted deletions of 11beta-hydroxysteroid dehydrogenases 1 and 2 genes. Mol Cell Endocrinol. 2001;171:15–20.CrossRefPubMed
37.
Seckl JR, Morton NM, Chapman KE, et al. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res. 2004;59:359–93.CrossRefPubMed
38.
Walker EA, Stewart PM. 11beta-hydroxysteroid dehydrogenase: unexpected connections. Trends Endocrinol Metab. 2003;14:334–9.CrossRefPubMed
39.
Boza C, Riquelme A, Ibanez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15:1148–53.CrossRefPubMed
40.
Paterson JM, Seckl JR, Mullins JJ. Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice. Am J Physiol Regul Integr Comp Physiol. 2005;289:R642–52.PubMed
41.
Liew PL, Lee WJ, Lee YC, et al. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease. Obes Surg. 2006;16:1584–93.CrossRefPubMed
42.
Arun J, Clements RH, Lazenby AJ, et al. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg. 2006;16:1351–8.CrossRefPubMed
43.
Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:285–91.CrossRefPubMed
44.
Kannisto K, Pietilainen KH, Ehrenborg E, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab. 2004;89:4414–21.CrossRefPubMed
45.
Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs. 2008;17:481–96.CrossRefPubMed
46.
Friedman TC, Mastorakos G, Newman TD, et al. Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J. 1996;43:645–55.CrossRefPubMed
47.
Jezkova J, Marek J, Prazny M, et al. Effect of hypercortisolism on development of atherosclerotic changes in blood vessels. Vnitr Lek. 2003;49:656–67.PubMed
48.
Yoshida C, Miyachi Y. Lipid metabolism in Cushing's syndrome. Nippon Rinsho. 2001;59(Suppl 3):177–80.PubMed
49.
Nuotio-Antar AM, Hachey DL, Hasty AH. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab. 2007;293:E1517–28.CrossRefPubMed
50.
51.
Wake DJ, Rask E, Livingstone DE, et al. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab. 2003;88:3983–8.CrossRefPubMed
52.
Turpeinen U, Markkanen H, Sane T, et al. Determination of free tetrahydrocortisol and tetrahydrocortisone ratio in urine by liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest. 2006;66:147–59.CrossRefPubMed
Metadata
Title
Overexpression of 11β-Hydroxysteroid Dehydrogenase Type 1 in Hepatic and Visceral Adipose Tissue is Associated with Metabolic Disorders in Morbidly Obese Patients
Authors
René Baudrand
Cristian A. Carvajal
Arnoldo Riquelme
Mauricio Morales
Nancy Solis
Margarita Pizarro
Alex Escalona
Camilo Boza
Gustavo Pérez
Angélica Domínguez
Marco Arrese
Carlos E. Fardella
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 1/2010
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-009-9937-0

Other articles of this Issue 1/2010

Obesity Surgery 1/2010 Go to the issue

Clinical Research

Reduction in Plasma Levels of Inflammatory and Oxidative Stress Indicators After Roux-En-Y Gastric Bypass

Letter to the Editor

Preoperative Weight Loss: A Component of the Preoperative Program in Bariatric Surgery

Clinical Research

The Impact of Reconstructive Procedures Following Bariatric Surgery on Patient Well-being and Quality of Life

Basic Science Research

Adipocyte Accumulation of Long-Chain Fatty Acids in Obesity is Multifactorial, Resulting from Increased Fatty Acid Uptake and Decreased Activity of Genes Involved in Fat Utilization

Clinical Research

Comparison Between the Results of Laparoscopic Sleeve Gastrectomy and Laparoscopic Roux-en-Y Gastric Bypass in the Indian Population: A Retrospective 1 Year Study

Invited Commentary

Sleeve Gastrectomy for Childhood Morbid Obesity: Why Not?